Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NU19
UPID:
TB22B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NU19; A8KA28; Q32MQ8; Q5VUK9; Q6P4C3; Q7Z6P7; Q9BPV6; Q9BUT5; Q9NXB6
Background:
TBC1 domain family member 22B plays a crucial role in cellular processes by potentially acting as a GTPase-activating protein for Rab family proteins. This function is vital for the regulation of intracellular membrane trafficking and dynamics.
Therapeutic significance:
Understanding the role of TBC1 domain family member 22B could open doors to potential therapeutic strategies. Its involvement in cellular trafficking processes makes it a candidate for targeting in diseases where these pathways are disrupted.